Physician profile
Michael Harris Callahan
NPI 1063564243
$2,725.13
in general payments reported to CMS, 2019-2025
12 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.43 · 2020: $158 · 2021: $272 · 2022: $1,130 · 2023: $195 · 2024: $230 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,356.54 | 2021-2025 | Scopis Ent, Hemopore |
| Aerin Medical INC. | $329.56 | 2022-2025 | |
| Optinose US, INC. | $271.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $228.95 | 2020-2025 | Dupixent |
| Genzyme Corporation | $164.65 | 2019-2025 | |
| Integra Lifesciences Corporation | $150.00 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Inspire Medical Systems, INC. | $71.97 | 2025 | Inspire |
| Intersect Ent, INC. | $67.99 | 2020 | |
| Tactile Systems Technology INC | $36.99 | 2023 | Flexitouch Plus, Entre Plus |
| Merck Sharp & Dohme LLC | $25.15 | 2023 | |
| Glaxosmithkline, LLC. | $14.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $6.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.